GlobeNewswire: Coherus BioSciences, Inc. Contains the last 10 of 353 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T14:30:58ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/13/2845826/0/en/Coherus-BioSciences-Reports-Fourth-Quarter-Full-Year-2023-Financial-Results-and-Provides-Current-Business-Update.html?f=22&fvtc=4&fvtv=24032Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update2024-03-13T20:01:00Z<![CDATA[– Net revenue of $91.5 million in the fourth quarter and $257.2 million in FY 2023 –]]>https://www.globenewswire.com/news-release/2024/03/05/2840881/0/en/Coherus-to-Report-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-13-2024.html?f=22&fvtc=4&fvtv=24032Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 20242024-03-05T21:01:00Z<![CDATA[REDWOOD CITY, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its fourth quarter and full year 2023 financial results will be released after market close on Wednesday, March 13, 2024. Starting at 5:00 pm ET on March 13, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.]]>https://www.globenewswire.com/news-release/2024/03/04/2839218/0/en/Coherus-Completes-Divestiture-of-Ophthalmology-Franchise.html?f=22&fvtc=4&fvtv=24032Coherus Completes Divestiture of Ophthalmology Franchise2024-03-04T06:00:00Z<![CDATA[– Upfront cash payment of $170 million strengthens capital structure –]]>https://www.globenewswire.com/news-release/2024/02/23/2834681/0/en/Coherus-BioSciences-Announces-New-Employment-Inducement-Grants.html?f=22&fvtc=4&fvtv=24032Coherus BioSciences Announces New Employment Inducement Grants2024-02-23T22:33:13Z<![CDATA[REDWOOD CITY, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that effective February 20, 2024, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 170,000 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $2.59, the closing trading price on the grant date. One Executive Vice President level executive was granted an option to purchase 150,000 shares; and two additional non-officer employees were granted options to purchase an aggregate of 20,000 shares.]]>https://www.globenewswire.com/news-release/2024/02/21/2832750/0/en/Coherus-Announces-U-S-Launch-of-UDENYCA-ONBODY-a-Novel-and-Proprietary-State-of-the-Art-Delivery-System-for-pegfilgrastim-cbqv.html?f=22&fvtc=4&fvtv=24032Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv2024-02-21T13:30:00Z<![CDATA[– Innovative design enables five-minute pegfilgrastim-cbqv delivery time –]]>UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqvFull Prescribing Information, including instructions for use, is available at www.UDENYCA.comUDENYCA ONBODY™https://www.globenewswire.com/news-release/2024/02/05/2823475/0/en/Coherus-Amends-Term-Loan-Agreement-with-Pharmakon-Advisors-LP.html?f=22&fvtc=4&fvtv=24032Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP2024-02-05T13:00:00Z<![CDATA[- Estimated balance of $75 million upon $175 million paydown of principal projected in Q2 2024 - - Revenue covenant reduced to $125 million - - Term loan annual interest expense projected to be reduced by ~70% -]]>https://www.globenewswire.com/news-release/2024/01/22/2812687/0/en/Coherus-Announces-Agreement-to-Divest-Ophthalmology-Franchise-to-Sandoz-in-170-Million-Upfront-All-Cash-Deal.html?f=22&fvtc=4&fvtv=24032Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal2024-01-22T06:15:00Z<![CDATA[– Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –]]>https://www.globenewswire.com/news-release/2024/01/18/2811956/0/en/Coherus-Presents-Positive-Phase-2-Clinical-Data-on-Casdozokitug-a-First-in-Class-IL-27-Targeted-Antibody-at-the-2024-ASCO-GI-Cancers-Symposium.html?f=22&fvtc=4&fvtv=24032Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium2024-01-18T21:05:00Z<![CDATA[– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –]]>https://www.globenewswire.com/news-release/2024/01/03/2803378/0/en/Coherus-BioSciences-Management-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html?f=22&fvtc=4&fvtv=24032Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference2024-01-03T14:00:00Z<![CDATA[REDWOOD CITY, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” Nasdaq: CHRS), today announced that senior management will present at the upcoming 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 9:45 a.m. Pacific Time. The presentation and Q&A session will be accessible via Webcast through a link posted on the Investor Events Calendar section of the Coherus website: https://investors.coherus.com/upcoming-events. This webcast will be available for replay until February 9, 2024.]]>https://www.globenewswire.com/news-release/2024/01/02/2802665/0/en/Coherus-Announces-U-S-Launch-of-LOQTORZI.html?f=22&fvtc=4&fvtv=24032Coherus Announces U.S. Launch of LOQTORZI™2024-01-02T13:29:00Z<![CDATA[– Launch of LOQTORZI offers first and only FDA-approved treatment for NPC in all lines of therapy –]]>LOQTORZI™ (toripalimab-tpzi) product imageLOQTORZI™ (toripalimab-tpzi)